Schweizer, M. T., Chakrabarti, J., Narayanan, S., Lin, S. (2025). Mevrometostat (PF-06821497) in combination with enzalutamide for androgen receptor pathway inhibitor (ARPI)-naïve patients with metastatic castration-resistant prostate cancer (mCRPC): The phase 3, randomized MEVPRO-2 trial.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.5_suppl.tps287